The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... Among ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... deal for Immunomedics (with the drug ...
MarketBeat on MSN4d
Gilead's Stock Surge: What's Fueling the Momentum?Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Gilead Sciences (GILD – Research Report) yesterday and set a price ...
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...
The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback